- Home
- BAM vs GSK Comparison
BAM vs GSK Comparison
Compare BAM & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAM
- GSK
- Stock Information
- Founded
- BAM 2022
- GSK 1715
- Country
- BAM United States
- GSK United Kingdom
- Employees
- BAM N/A
- GSK N/A
- Industry
- BAM
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- BAM
- GSK Health Care
- Exchange
- BAM Nasdaq
- GSK Nasdaq
- Market Cap
- BAM 89.7B
- GSK 86.1B
- IPO Year
- BAM N/A
- GSK N/A
- Fundamental
- Price
- BAM $54.37
- GSK $38.04
- Analyst Decision
- BAM Buy
- GSK Hold
- Analyst Count
- BAM 13
- GSK 3
- Target Price
- BAM $57.15
- GSK N/A
- AVG Volume (30 Days)
- BAM 2.2M
- GSK 4.9M
- Earning Date
- BAM 08-06-2025
- GSK 07-30-2025
- Dividend Yield
- BAM 3.22%
- GSK 4.23%
- EPS Growth
- BAM 35.02
- GSK N/A
- EPS
- BAM 1.46
- GSK 0.98
- Revenue
- BAM $4,177,000,000.00
- GSK $40,735,668,430.00
- Revenue This Year
- BAM $33.64
- GSK $6.70
- Revenue Next Year
- BAM $13.78
- GSK $5.42
- P/E Ratio
- BAM $37.22
- GSK $18.78
- Revenue Growth
- BAM 7.32
- GSK 2.57
- 52 Week Low
- BAM $37.33
- GSK $31.72
- 52 Week High
- BAM $62.61
- GSK $44.67
- Technical
- Relative Strength Index (RSI)
- BAM 43.94
- GSK 40.16
- Support Level
- BAM $53.67
- GSK $40.67
- Resistance Level
- BAM $55.89
- GSK $42.63
- Average True Range (ATR)
- BAM 1.10
- GSK 0.66
- MACD
- BAM -0.39
- GSK -0.41
- Stochastic Oscillator
- BAM 17.20
- GSK 4.67
About BAM Brookfield Asset Management Inc Limited Voting Shares
Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.